Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Open-label phase 3 extension of adalimumab in moderate to severe hidradenitis suppurativa
NL-OMON39701Phase 3Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Jan 2013
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, open-label, single-arm trial of adalimumab in hidradenitis suppurativa (HS), sponsored by AbbVie Inc. Started Jan 2013; status: active, not recruiting.
02
Drugs
03
Conditions
hidradenitis suppurativa (HS)
Beyond the preview
Go deeper on NL-OMON39701.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON39701.